SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000891293-17-000114
Filing Date
2017-11-07
Accepted
2017-11-06 17:36:00
Documents
47
Period of Report
2017-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q cti10q09302017.htm 10-Q 975459
2 EXHIBIT 10.3 ex103-fifthamendmenttoloan.htm EX-10.3 32397
3 EXHIBIT 31.1 ex311-cti10q09302017.htm EX-31.1 11007
4 EXHIBIT 31.2 ex312-cti10q09302017.htm EX-31.2 12132
5 EXHIBIT 32 ex32-cti10q09302017.htm EX-32 11905
  Complete submission text file 0000891293-17-000114.txt   3489170

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT ctic-20170930.xml EX-101.INS 445676
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ctic-20170930.xsd EX-101.SCH 25716
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ctic-20170930_cal.xml EX-101.CAL 63320
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ctic-20170930_def.xml EX-101.DEF 115386
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ctic-20170930_lab.xml EX-101.LAB 382535
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ctic-20170930_pre.xml EX-101.PRE 222279
Mailing Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: WA | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-28386 | Film No.: 171180437
SIC: 2834 Pharmaceutical Preparations